A PK2/Bv8/PROK2 Antagonist Suppresses Tumorigenic Processes by Inhibiting Angiogenesis in Glioma and Blocking Myeloid Cell Infiltration in Pancreatic Cancer

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Curtis, Valerie F ^a   Wang, Hui ^a   Yang, Pengyuan ^a   McLendon, Roger E ^a   Li, Xiaohan ^b   Zhou, Qun Yong ^b   Wang, Xiao Fan ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CHEMOKINE; CHEMOKINE RECEPTOR; GEMCITABINE; PKRA 7; PROTEIN PK2; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BRANCHING MORPHOGENESIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SIZE; CELL INFILTRATION; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; ENDOTHELIAL CELLS; GASTROINTESTINAL HORMONES; GLIOMA; HUMANS; MACROPHAGES; MICE; MYELOID CELLS; NEOVASCULARIZATION, PATHOLOGIC; NERVE TISSUE PROTEINS; NEUROPEPTIDES; PANCREATIC NEOPLASMS; TUMOR BURDEN; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84872797793     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054916     Document Type: Article

References (51)

1. Shojaei F, Zhong C, Wu X, Yu L, Ferrara N, (2008) Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol 18: 372-378.
2. Pollard JW, (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71-78.
3. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, et al. (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58: 49-59.
4. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, et al. (2004) Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6: 409-421.
5. Kusmartsev S, Gabrilovich DI, (2006) Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 55: 237-245.
6. Shojaei F, Ferrara N, (2008) Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res 68: 5501-5504.
7. Zhou QY, (2006) The prokineticins: a novel pair of regulatory peptides. Mol Interv 6: 330-338.
8. Shojaei F, Wu X, Zhong C, Yu L, Liang XH, et al. (2007) Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450: 825-831.
9. Franchi S, Giannini E, Lattuada D, Lattanzi R, Tian H, et al. (2008) The prokineticin receptor agonist Bv8 decreases IL-10 and IL-4 production in mice splenocytes by activating prokineticin receptor-1. BMC Immunol 9: 60.
10. Martucci C, Franchi S, Giannini E, Tian H, Melchiorri P, et al. (2006) Bv8, the amphibian homologue of the mammalian prokineticins, induces a proinflammatory phenotype of mouse macrophages. Br J Pharmacol 147: 225-234.
11. Guilini C, Urayama K, Turkeri G, Dedeoglu DB, Kurose H, et al. (2010) Divergent roles of prokineticin receptors in the endothelial cells: angiogenesis and fenestration. Am J Physiol Heart Circ Physiol 298: H844-852.
12. Urayama K, Dedeoglu DB, Guilini C, Frantz S, Ertl G, et al. (2009) Transgenic myocardial overexpression of prokineticin receptor-2 (GPR73b) induces hypertrophy and capillary vessel leakage. Cardiovasc Res 81: 28-37.
13. Urayama K, Guilini C, Messaddeq N, Hu K, Steenman M, et al. (2007) The prokineticin receptor-1 (GPR73) promotes cardiomyocyte survival and angiogenesis. FASEB J 21: 2980-2993.
14. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, et al. (2010) Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 12: 233-242.
15. Korc M, (2007) Pancreatic cancer-associated stroma production. Am J Surg 194: S84-86.
16. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, et al. (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70: 779-787.
17. Badie B, Schartner JM (2000) Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery 46: 957-961; discussion 961-952.
18. Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, et al. (2011) Significance of m2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 167: e211-219.
19. Roggendorf W, Strupp S, Paulus W, (1996) Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol 92: 288-293.
20. Cummings TJ, Hulette CM, Bigner SH, Riggins GJ, McLendon RE, (2001) Ham56-immunoreactive macrophages in untreated infiltrating gliomas. Arch Pathol Lab Med 125: 637-641.
21. Lin DC, Bullock CM, Ehlert FJ, Chen JL, Tian H, et al. (2002) Identification and molecular characterization of two closely related G protein-coupled receptors activated by prokineticins/endocrine gland vascular endothelial growth factor. J Biol Chem 277: 19276-19280.
22. Bullock CM, Li JD, Zhou QY, (2004) Structural determinants required for the bioactivities of prokineticins and identification of prokineticin receptor antagonists. Mol Pharmacol 65: 582-588.
23. Donovan D, Brown NJ, Bishop ET, Lewis CE, (2001) Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo. Angiogenesis 4: 113-121.
24. Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ, et al. (1994) Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc Natl Acad Sci U S A 91: 2752-2756.
25. Wong B, Lumma WC, Smith AM, Sisko JT, Wright SD, et al. (2001) Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J Leukoc Biol 69: 959-962.
26. Bei R, Marzocchella L, Turriziani M, (2010) The use of temozolomide for the treatment of malignant tumors: clinical evidence and molecular mechanisms of action. Recent Pat Anticancer Drug Discov 5: 172-187.
27. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
28. Cheng CL, Johnson SP, Keir ST, Quinn JA, Ali-Osman F, et al. (2005) Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 4: 1364-1368.
29. Patel VJ, Elion GB, Houghton PJ, Keir S, Pegg AE, et al. (2000) Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin Cancer Res 6: 4154-4157.
30. Damaraju VL, Bouffard DY, Wong CK, Clarke ML, Mackey JR, et al. (2007) Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer. BMC Cancer 7: 121.
31. Nyberg P, Salo T, Kalluri R, (2008) Tumor microenvironment and angiogenesis. Front Biosci 13: 6537-6553.
32. Ferrara N, (2010) Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis. Curr Opin Hematol 17: 219-224.
33. Casanovas O, Hicklin DJ, Bergers G, Hanahan D, (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309.
34. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, et al. (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239.
35. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
36. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, et al. (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2: 306-314.
37. Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, et al. (2009) G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A 106: 6742-6747.
38. Shojaei F, Ferrara N, (2008) Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist Updat 11: 219-230.
39. Shojaei F, Singh M, Thompson JD, Ferrara N, (2008) Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A 105: 2640-2645.
40. Dempke WC, Heinemann V, (2009) Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer 45: 1117-1128.
41. Takahashi Y, Nishioka K, (2011) Therapeutic approaches targeting tumor vasculature in gastrointestinal cancers. Front Biosci (Elite Ed) 3: 541-548.
42. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, et al. (2007) Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 67: 9518-9527.
43. Ishida T, Ueda R, (2006) CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 97: 1139-1146.
44. Wen H, Hogaboam CM, Lukacs NW, Cook DN, Lira SA, et al. (2007) The chemokine receptor CCR6 is an important component of the innate immune response. Eur J Immunol 37: 2487-2498.
45. Wang H, Lathia JD, Wu Q, Wang J, Li Z, et al. (2009) Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 27: 2393-2404.
46. Ma C, Rong Y, Radiloff DR, Datto MB, Centeno B, et al. (2008) Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev 22: 308-321.
47. Lee NY, Ray B, How T, Blobe GC, (2008) Endoglin promotes transforming growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. J Biol Chem 283: 32527-32533.
48. Li Z, Bao S, Wu Q, Wang H, Eyler C, et al. (2009) Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15: 501-513.
49. Rich JN, Sathornsumetee S, Keir ST, Kieran MW, Laforme A, et al. (2005) ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res 11: 8145-8157.
50. DeCoursey TE, Kim SY, Silver MR, Quandt FN, (1996) Ion channel expression in PMA-differentiated human THP-1 macrophages. J Membr Biol 152: 141-157.
51. Kim SY, Silver MR, DeCoursey TE, (1996) Ion channels in human THP-1 monocytes. J Membr Biol 152: 117-130.